Deltoid muscle

Delt Partners with Reliance Cyber to Offer Industry-leading Cybersecurity Services to the Public Sector

Retrieved on: 
Wednesday, April 26, 2023

LONDON, April 26, 2023 /PRNewswire/ -- Delt, one of the country's foremost shared services providers, has joined forces with Reliance Cyber - a leading cybersecurity company - to deliver robust cybersecurity services to public sector organisations.

Key Points: 
  • LONDON, April 26, 2023 /PRNewswire/ -- Delt, one of the country's foremost shared services providers, has joined forces with Reliance Cyber - a leading cybersecurity company - to deliver robust cybersecurity services to public sector organisations.
  • As a shared services provider, Delt is dedicated to providing IT and cybersecurity to public sector organisations in the South West of England.
  • Rob Walton, Chief Revenue Officer at Reliance Cyber, added, "We are proud to work with Delt in protecting public sector organisations from the mounting threat of cyberattacks.
  • The Delt and Reliance Cyber partnership is set to enhance the cybersecurity of public sector organisations and provide Delt's customers with peace of mind, knowing that they are protected by the best possible security service in the market.

Delt Partners with Reliance Cyber to Offer Industry-leading Cybersecurity Services to the Public Sector

Retrieved on: 
Wednesday, April 26, 2023

LONDON, April 26, 2023 /PRNewswire/ -- Delt, one of the country's foremost shared services providers, has joined forces with Reliance Cyber - a leading cybersecurity company - to deliver robust cybersecurity services to public sector organisations.

Key Points: 
  • LONDON, April 26, 2023 /PRNewswire/ -- Delt, one of the country's foremost shared services providers, has joined forces with Reliance Cyber - a leading cybersecurity company - to deliver robust cybersecurity services to public sector organisations.
  • As a shared services provider, Delt is dedicated to providing IT and cybersecurity to public sector organisations in the South West of England.
  • Rob Walton, Chief Revenue Officer at Reliance Cyber, added, "We are proud to work with Delt in protecting public sector organisations from the mounting threat of cyberattacks.
  • The Delt and Reliance Cyber partnership is set to enhance the cybersecurity of public sector organisations and provide Delt's customers with peace of mind, knowing that they are protected by the best possible security service in the market.

Ease-of-Use and Potential Self-Administration of Vaccination Shown with Vaxxas High Density Microarray Patch (HD-MAP)

Retrieved on: 
Thursday, March 30, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density microarray patch (HD-MAP) to effectively deliver vaccine payloads when used either by trained professionals or individual self-administration.

Key Points: 
  • Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density microarray patch (HD-MAP) to effectively deliver vaccine payloads when used either by trained professionals or individual self-administration.
  • The data reported in Human Vaccines & Immunotherapeutics , demonstrated equivalency of observed human skin response and vaccine delivery potential when comparing administration by a trained professional versus participant patch self-administration.
  • The clinical study in this article involved twenty healthy participants (n=20) who were between 18-45 years old, 65 percent of whom were female.
  • The HD-MAP was shown to be safe and well-tolerated by study participants, with no serious adverse events reported.

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Retrieved on: 
Wednesday, January 18, 2023

Results from this Cybin-sponsored study are intended to inform the future pathway for this program.

Key Points: 
  • Results from this Cybin-sponsored study are intended to inform the future pathway for this program.
  • “The results from the feasibility study are very promising and provide further insights into the potential of this cutting-edge wearable technology to quantify neural activity and changes in brain biomarkers during the administration of psychedelics.
  • Key Findings from the Feasibility Study:
    Demonstrated ketamine-induced changes to functional brain biomarkers associated with potential therapeutic effects, including alterations in cortical function associated with psychedelic experiences.
  • The feasibility study received U.S. Food and Drug Administration Investigational New Drug authorization in October 2021 and U.S. Institutional Review Board approval in January 2022.